Loading
companiesCompany
ARCAGY-GINECO
aka GINECO, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, ARCAGY
The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.
Overview
GINECO was founded in 1993 as France's cooperative group for ovarian, endometrial, cervical and rare gynaecologic cancers, with ARCAGY as its academic sponsor and research organisation. As a founding member of the European ENGOT network and the Gynecologic Cancer InterGroup, it led PAOLA-1/ENGOT-ov25, which showed olaparib plus bevacizumab maintenance improves progression-free and, in HRD-positive disease, overall survival in newly diagnosed ovarian cancer. GINECO also ran the CHIVA and ICON7 contributions, elderly-specific ovarian trials and the rare-tumour TMRG network, and it co-develops immunotherapy trials in endometrial and cervical cancer with the GOG Foundation.
Headquarters
Paris, FR
Scorecard
All companies#84of 1243 companies, score 54
- approved products +12
- targets +4
- modalities +2
- regions +6
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 2 targets, 485 registry studies. Formula on the scorecards page.
Website
Founded
1993
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-11.
Matched to Arcagy Gineco (high confidence name match), including child institutions. 90 works · 1,599 citations · 72% open access · 13% clinical trials · 0% reviews.
Oncology works per year
242022
252023
152024
152025
112026
Most works
- Éric Pujade-Lauraine50 works
- Ignace Vergote34 works
- Isabelle Ray‐Coquard30 works
- Nicoletta Colombo27 works
- Philipp Harter18 works
- Antonio González-Martı́n16 works
- Keiichi Fujiwara16 works
- Domenica Lorusso15 works
- Bernard Asselain15 works
- Sandro Pignata14 works
Most cited
Isabelle Ray-Coquard
Professor of Medical Oncology, Centre Léon Bérard and Université Claude Bernard Lyon 1; President, GINECO
Ovarian cancerRare gynaecological tumoursPARP inhibitor combinations
Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers.
Sébastien Armanet
Directeur Général (Director General) of ARCAGY-GINECO
Clinical research operationsGynaecological oncology trialsAcademic cooperative groups
Director General who runs the operational team of ARCAGY-GINECO, the French non-profit academic research group for gynaecological and metastatic breast cancers.
Notes
top- PAOLA-1 (olaparib plus bevacizumab)
- Elderly ovarian cancer trials
- ENGOT and GCIG leadership
- Rare gynaecologic tumours network
Similar pages
not linked directly; found by shared links- CompanyMRC Clinical Trials Unit at UCL
Shares GOG-0218 & ICON7 (bevacizumab), Ovarian cancer and the tag cooperative-group.
- CompanyIntergroupe Francophone de Cancérologie Thoracique
- CompanyNRG Oncology
Shares GOG Foundation, Olaparib, Endometrial cancer, Cervical cancer and the tag cooperative-group.
- CompanyBreast Cancer Trials
Shares PARP inhibitors, Olaparib and the tag cooperative-group.
- CompanyKorean Gynecologic Oncology Group
Shares Endometrial cancer and the tag cooperative-group.
- CompanyBreast International Group (BIG)
Shares Olaparib and the tag cooperative-group.
- CompanyAGO Study Group
Shares Ovarian cancer and the tag cooperative-group.
- CompanyTROG Cancer Research
Shares Endometrial cancer and the tag cooperative-group.